221 related articles for article (PubMed ID: 1899564)
21. Phosphorylation of human plasminogen activators and plasminogen.
Barlati S; De Petro G; Bona C; Paracini F; Tonelli M
FEBS Lett; 1995 Apr; 363(1-2):170-4. PubMed ID: 7537224
[TBL] [Abstract][Full Text] [Related]
22. Kinetic analysis of covalent hybrid plasminogen activators: effect of CNBr-degraded fibrinogen on kinetic parameters of Glu1-plasminogen activation.
Lee PP; Wohl RC; Boreisha IG; Robbins KC
Biochemistry; 1988 Sep; 27(19):7506-13. PubMed ID: 2974723
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies.
Grøndahl-Hansen J; Nielsen LS; Kristensen P; Grøndahl-Hansen V; Andreasen PA; Danø K
Br J Dermatol; 1985 Sep; 113(3):257-63. PubMed ID: 3933538
[TBL] [Abstract][Full Text] [Related]
24. Effects of a fucoidan on the activation of plasminogen by u-PA and t-PA.
Nishino T; Yamauchi T; Horie M; Nagumo T; Suzuki H
Thromb Res; 2000 Sep; 99(6):623-34. PubMed ID: 10974349
[TBL] [Abstract][Full Text] [Related]
25. Construction and expression of a hybrid plasminogen activator gene with sequences from non-protease region of tissue-type plasminogen activator (t-PA) and protease region of urokinase (u-PA).
Kalyan NK; Lee SG; Cheng SM; Hartzell R; Urbano C; Hung PP
Gene; 1988 Sep; 68(2):205-12. PubMed ID: 3146528
[TBL] [Abstract][Full Text] [Related]
26. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor.
Mars WM; Kim TH; Stolz DB; Liu ML; Michalopoulos GK
Cancer Res; 1996 Jun; 56(12):2837-43. PubMed ID: 8665523
[TBL] [Abstract][Full Text] [Related]
27. Modulation of plasminogen activator systems by matrix components in two breast cancer cell lines: MCF-7 and MDA-MB-231.
Pourreau-Schneider N; Delori P; Boutière B; Arnoux D; George F; Sampol J; Martin PM
J Natl Cancer Inst; 1989 Feb; 81(4):259-66. PubMed ID: 2492346
[TBL] [Abstract][Full Text] [Related]
28. Production of proteases type plasminogen activator and their inhibitor in cornea.
Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
[TBL] [Abstract][Full Text] [Related]
29. Effects of retinoic acid on plasminogen activators in murine epidermal cell culture.
Brown JM; Cohen RL; Chambers DA
Ann N Y Acad Sci; 1992 Dec; 667():50-1. PubMed ID: 1309071
[No Abstract] [Full Text] [Related]
30. Urokinase-type plasminogen activator is increased in the involuting ventral prostate of castrated rats.
Andreasen PA; Kristensen P; Lund LR; Danø K
Endocrinology; 1990 May; 126(5):2567-76. PubMed ID: 2109689
[TBL] [Abstract][Full Text] [Related]
31. Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix.
Grøndahl-Hansen J; Kirkeby LT; Ralfkiaer E; Kristensen P; Lund LR; Danø K
Am J Pathol; 1989 Oct; 135(4):631-6. PubMed ID: 2508479
[TBL] [Abstract][Full Text] [Related]
32. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
Fowler B; Mackman N; Parmer RJ; Miles LA
Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
[TBL] [Abstract][Full Text] [Related]
33. Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase.
Ke SH; Coombs GS; Tachias K; Navre M; Corey DR; Madison EL
J Biol Chem; 1997 Jun; 272(26):16603-9. PubMed ID: 9195973
[TBL] [Abstract][Full Text] [Related]
34. Properties of urokinase type-plasminogen activator found in chest fluid.
Hayashi S; Yamada K
Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):105-15. PubMed ID: 2109919
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a tissue-type plasminogen activator from porcine urine.
Zacharias U; Will H
FEBS Lett; 1991 Sep; 289(2):155-8. PubMed ID: 1915841
[TBL] [Abstract][Full Text] [Related]
36. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor.
Piedagnel R; Tiger Y; Lelongt B; Ronco PM
J Cell Physiol; 2006 Feb; 206(2):394-401. PubMed ID: 16155905
[TBL] [Abstract][Full Text] [Related]
37. Directing sequence-specific proteolysis to new targets. The influence of loop size and target sequence on selective proteolysis by tissue-type plasminogen activator and urokinase-type plasminogen activator.
Coombs GS; Bergstrom RC; Madison EL; Corey DR
J Biol Chem; 1998 Feb; 273(8):4323-8. PubMed ID: 9468480
[TBL] [Abstract][Full Text] [Related]
38. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
Gyetko MR; Webb AC; Sitrin RG
J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
[TBL] [Abstract][Full Text] [Related]
39. Purification and characterization of human kidney plasminogen activator dissimilar to urokinase.
Sueishi K; Nanno S; Okamura T; Inoue S; Tanaka K
Biochim Biophys Acta; 1982 Aug; 717(2):327-36. PubMed ID: 7052141
[TBL] [Abstract][Full Text] [Related]
40. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
